nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—ACHE—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.0318	0.132	CbGpPWpGaD
Procainamide—SCN11A—nervous system—Gilles de la Tourette syndrome	0.0266	0.0381	CbGeAlD
Procainamide—SCN11A—central nervous system—Gilles de la Tourette syndrome	0.0256	0.0366	CbGeAlD
Procainamide—SCN9A—midbrain—Gilles de la Tourette syndrome	0.0215	0.0308	CbGeAlD
Procainamide—DNMT1—midbrain—Gilles de la Tourette syndrome	0.0211	0.0302	CbGeAlD
Procainamide—SCN11A—brain—Gilles de la Tourette syndrome	0.0203	0.0291	CbGeAlD
Procainamide—SCN8A—nervous system—Gilles de la Tourette syndrome	0.0201	0.0288	CbGeAlD
Procainamide—SCN8A—central nervous system—Gilles de la Tourette syndrome	0.0194	0.0278	CbGeAlD
Procainamide—SCN1A—midbrain—Gilles de la Tourette syndrome	0.0185	0.0265	CbGeAlD
Procainamide—ACHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0183	0.076	CbGpPWpGaD
Procainamide—Chloroprocaine—SLC6A3—Gilles de la Tourette syndrome	0.0182	0.297	CrCbGaD
Procainamide—Procaine—SLC6A3—Gilles de la Tourette syndrome	0.0174	0.283	CrCbGaD
Procainamide—DNMT1—nervous system—Gilles de la Tourette syndrome	0.0174	0.0249	CbGeAlD
Procainamide—SCN7A—brain—Gilles de la Tourette syndrome	0.0173	0.0247	CbGeAlD
Procainamide—ACHE—midbrain—Gilles de la Tourette syndrome	0.0172	0.0246	CbGeAlD
Procainamide—SCN2A—midbrain—Gilles de la Tourette syndrome	0.017	0.0243	CbGeAlD
Procainamide—DNMT1—central nervous system—Gilles de la Tourette syndrome	0.0167	0.0239	CbGeAlD
Procainamide—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0163	0.0678	CbGpPWpGaD
Procainamide—SCN4A—nervous system—Gilles de la Tourette syndrome	0.0158	0.0226	CbGeAlD
Procainamide—SCN8A—brain—Gilles de la Tourette syndrome	0.0154	0.022	CbGeAlD
Procainamide—SCN1A—nervous system—Gilles de la Tourette syndrome	0.0152	0.0218	CbGeAlD
Procainamide—Metoclopramide—DRD3—Gilles de la Tourette syndrome	0.0152	0.248	CrCbGaD
Procainamide—SCN4A—central nervous system—Gilles de la Tourette syndrome	0.0152	0.0218	CbGeAlD
Procainamide—SCN3A—midbrain—Gilles de la Tourette syndrome	0.0149	0.0214	CbGeAlD
Procainamide—SCN1A—central nervous system—Gilles de la Tourette syndrome	0.0147	0.021	CbGeAlD
Procainamide—SLC22A2—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0146	0.0605	CbGpPWpGaD
Procainamide—SCN2A—nervous system—Gilles de la Tourette syndrome	0.014	0.02	CbGeAlD
Procainamide—SLC22A1—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0136	0.0564	CbGpPWpGaD
Procainamide—SCN9A—brain—Gilles de la Tourette syndrome	0.0135	0.0194	CbGeAlD
Procainamide—SCN10A—nervous system—Gilles de la Tourette syndrome	0.0135	0.0193	CbGeAlD
Procainamide—SCN2A—central nervous system—Gilles de la Tourette syndrome	0.0135	0.0193	CbGeAlD
Procainamide—DNMT1—brain—Gilles de la Tourette syndrome	0.0133	0.019	CbGeAlD
Procainamide—SCN10A—central nervous system—Gilles de la Tourette syndrome	0.013	0.0186	CbGeAlD
Procainamide—SCN3A—nervous system—Gilles de la Tourette syndrome	0.0123	0.0176	CbGeAlD
Procainamide—SCN5A—nervous system—Gilles de la Tourette syndrome	0.0122	0.0175	CbGeAlD
Procainamide—SCN4A—brain—Gilles de la Tourette syndrome	0.0121	0.0173	CbGeAlD
Procainamide—SCN3A—central nervous system—Gilles de la Tourette syndrome	0.0118	0.0169	CbGeAlD
Procainamide—SCN5A—central nervous system—Gilles de la Tourette syndrome	0.0118	0.0169	CbGeAlD
Procainamide—SCN1A—brain—Gilles de la Tourette syndrome	0.0116	0.0167	CbGeAlD
Procainamide—ACHE—brain—Gilles de la Tourette syndrome	0.0108	0.0154	CbGeAlD
Procainamide—SCN2A—brain—Gilles de la Tourette syndrome	0.0107	0.0153	CbGeAlD
Procainamide—Metoclopramide—DRD2—Gilles de la Tourette syndrome	0.0105	0.172	CrCbGaD
Procainamide—CHRM2—nervous system—Gilles de la Tourette syndrome	0.0104	0.0149	CbGeAlD
Procainamide—SCN10A—brain—Gilles de la Tourette syndrome	0.0103	0.0148	CbGeAlD
Procainamide—SLC22A1—nervous system—Gilles de la Tourette syndrome	0.0102	0.0147	CbGeAlD
Procainamide—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.01	0.0144	CbGeAlD
Procainamide—SLC22A1—central nervous system—Gilles de la Tourette syndrome	0.00986	0.0141	CbGeAlD
Procainamide—SLC22A3—nervous system—Gilles de la Tourette syndrome	0.00979	0.014	CbGeAlD
Procainamide—SLC22A3—central nervous system—Gilles de la Tourette syndrome	0.00942	0.0135	CbGeAlD
Procainamide—SCN3A—brain—Gilles de la Tourette syndrome	0.00939	0.0134	CbGeAlD
Procainamide—SCN5A—brain—Gilles de la Tourette syndrome	0.00936	0.0134	CbGeAlD
Procainamide—SLC22A5—midbrain—Gilles de la Tourette syndrome	0.00866	0.0124	CbGeAlD
Procainamide—BCHE—midbrain—Gilles de la Tourette syndrome	0.00843	0.0121	CbGeAlD
Procainamide—SLC22A4—brain—Gilles de la Tourette syndrome	0.00822	0.0118	CbGeAlD
Procainamide—CHRM2—brain—Gilles de la Tourette syndrome	0.00797	0.0114	CbGeAlD
Procainamide—SLC22A1—brain—Gilles de la Tourette syndrome	0.00783	0.0112	CbGeAlD
Procainamide—SLC22A3—brain—Gilles de la Tourette syndrome	0.00748	0.0107	CbGeAlD
Procainamide—SLC22A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00729	0.0303	CbGpPWpGaD
Procainamide—BCHE—nervous system—Gilles de la Tourette syndrome	0.00693	0.00993	CbGeAlD
Procainamide—SLC22A1—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00679	0.0282	CbGpPWpGaD
Procainamide—BCHE—central nervous system—Gilles de la Tourette syndrome	0.00667	0.00956	CbGeAlD
Procainamide—ACHE—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00603	0.0251	CbGpPWpGaD
Procainamide—SLC22A5—brain—Gilles de la Tourette syndrome	0.00544	0.00779	CbGeAlD
Procainamide—BCHE—brain—Gilles de la Tourette syndrome	0.0053	0.00759	CbGeAlD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00509	0.0212	CbGpPWpGaD
Procainamide—SLC22A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00506	0.021	CbGpPWpGaD
Procainamide—DNMT1—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.00503	0.0209	CbGpPWpGaD
Procainamide—SLC22A1—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00471	0.0196	CbGpPWpGaD
Procainamide—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00459	0.00658	CbGeAlD
Procainamide—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.00442	0.00633	CbGeAlD
Procainamide—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00434	0.018	CbGpPWpGaD
Procainamide—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00421	0.0175	CbGpPWpGaD
Procainamide—SLC22A4—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00418	0.0174	CbGpPWpGaD
Procainamide—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00393	0.0163	CbGpPWpGaD
Procainamide—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00365	0.0152	CbGpPWpGaD
Procainamide—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00354	0.0147	CbGpPWpGaD
Procainamide—CYP2D6—brain—Gilles de la Tourette syndrome	0.00351	0.00503	CbGeAlD
Procainamide—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0033	0.0137	CbGpPWpGaD
Procainamide—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00315	0.0131	CbGpPWpGaD
Procainamide—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00314	0.0131	CbGpPWpGaD
Procainamide—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00275	0.0114	CbGpPWpGaD
Procainamide—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00231	0.00961	CbGpPWpGaD
Procainamide—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00198	0.00822	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00193	0.00802	CbGpPWpGaD
Procainamide—SLC22A4—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.0019	0.0079	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00187	0.00778	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00186	0.00773	CbGpPWpGaD
Procainamide—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00184	0.00766	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00166	0.00689	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00154	0.0064	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00152	0.00631	CbGpPWpGaD
Procainamide—SLC22A3—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00143	0.00596	CbGpPWpGaD
Procainamide—SLC22A5—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00143	0.00594	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00139	0.00578	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.00133	0.00552	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00124	0.00516	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00123	0.0051	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00122	0.00508	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.00118	0.00492	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00117	0.00488	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00113	0.00469	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00113	0.00469	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00111	0.00461	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00109	0.00452	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—MET—Gilles de la Tourette syndrome	0.00109	0.00452	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.00108	0.0045	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00107	0.00443	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00103	0.0043	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00098	0.00407	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000965	0.00401	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000951	0.00395	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000903	0.00375	CbGpPWpGaD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000899	0.00374	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000876	0.00364	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000875	0.00364	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000849	0.00353	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000838	0.00348	CbGpPWpGaD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000837	0.00348	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000837	0.00348	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000816	0.00339	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000813	0.00338	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000804	0.00334	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000804	0.00334	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000793	0.0033	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000792	0.00329	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000776	0.00322	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000776	0.00322	CbGpPWpGaD
Procainamide—ACHE—Metabolism—HDC—Gilles de la Tourette syndrome	0.000771	0.00321	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MET—Gilles de la Tourette syndrome	0.000764	0.00318	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000758	0.00315	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000728	0.00303	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000726	0.00302	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000718	0.00298	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000697	0.0029	CbGpPWpGaD
Procainamide—BCHE—Metabolism—HDC—Gilles de la Tourette syndrome	0.000688	0.00286	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000649	0.0027	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000615	0.00256	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000573	0.00238	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000546	0.00227	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000545	0.00227	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000531	0.00221	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000531	0.00221	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000494	0.00205	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000457	0.0019	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000455	0.00189	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000426	0.00177	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000346	0.00144	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000316	0.00132	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000309	0.00128	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.0003	0.00125	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00028	0.00117	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000279	0.00116	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000272	0.00113	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000254	0.00105	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000196	0.000813	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000178	0.000739	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000166	0.000689	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000161	0.000669	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00015	0.000623	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000105	0.000436	CbGpPWpGaD
